I see a cup and handle forecast called out here, which is a possibility with the way the current COVID market is moving.
HTBX does have a few bright spots in early faces of trials, one of which for tumor destruction:
"PTX-35 is a novel, first-in-class agonist antibody targeting TNFRSF25, also known as death receptor 3 (DR3), a receptor that is preferentially expressed by antigen-experienced T cells."
Another of which, a phase 1 COVID trial:
"Jeff Wolf, CEO of Heat, commented, "We remain on track to complete design and development of our COVID-19 vaccine in July, and expect that our gp96/nCoV-2 expressing cell line will be available for clinical-grade manufacturing with our partner, Waisman Biomanufacturing, in early August. Given our progress to date, we remain encouraged by the potential of our unique vaccine to provide broad cellular T-cell and humoral protection against COVID-19, as well as possible future mutations or other coronaviruses.""
Each of these snippets made available via Yahoo.
Three options:
1) Sharp correction and continue to grow to higher highs
2) A bit of a prolonged correction, but still progress expected from the companies overall trends
3) Lower lows and a bust scenario
Trading stocks of this value is a very scary market, please do not take as financial advice and merely as informational.
HTBX does have a few bright spots in early faces of trials, one of which for tumor destruction:
"PTX-35 is a novel, first-in-class agonist antibody targeting TNFRSF25, also known as death receptor 3 (DR3), a receptor that is preferentially expressed by antigen-experienced T cells."
Another of which, a phase 1 COVID trial:
"Jeff Wolf, CEO of Heat, commented, "We remain on track to complete design and development of our COVID-19 vaccine in July, and expect that our gp96/nCoV-2 expressing cell line will be available for clinical-grade manufacturing with our partner, Waisman Biomanufacturing, in early August. Given our progress to date, we remain encouraged by the potential of our unique vaccine to provide broad cellular T-cell and humoral protection against COVID-19, as well as possible future mutations or other coronaviruses.""
Each of these snippets made available via Yahoo.
Three options:
1) Sharp correction and continue to grow to higher highs
2) A bit of a prolonged correction, but still progress expected from the companies overall trends
3) Lower lows and a bust scenario
Trading stocks of this value is a very scary market, please do not take as financial advice and merely as informational.